Get the Stockscreener App
1.61
0.62%
-0.01
Pre-market:
1.64
0.03
+1.86%
Gain Therapeutics Inc stock is traded at $1.61, with a volume of 192.99K.
It is down -0.62% in the last 24 hours and down -5.85% over the past month.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.
See More
Previous Close:
$1.62
Open:
$1.62
24h Volume:
192.99K
Relative Volume:
0.66
Market Cap:
$48.21M
Revenue:
$210.70K
Net Income/Loss:
$-21.37M
P/E Ratio:
-1.4636
EPS:
-1.1
Net Cash Flow:
$-21.10M
1W Performance:
-9.04%
1M Performance:
-5.85%
6M Performance:
-29.39%
1Y Performance:
+26.77%
1-Day Range:
$1.59
$1.66
1-Week Range:
$1.5251
$1.9349
52-Week Range:
$0.89
$3.19
Gain Therapeutics Inc Stock (GANX) Company Profile
Name
Gain Therapeutics Inc
Sector
Industry
Phone
(301) 500-1556
Address
4800 HAMPDEN LANE, BETHESDA
Compare GANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.61 | 53.00M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.27 | 123.14B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
550.00 | 60.43B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.69 | 42.07B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
572.71 | 34.47B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
290.35 | 27.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Gain Therapeutics Inc Stock (GANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Aug-14-24 | Resumed | Oppenheimer | Outperform |
| Apr-12-21 | Initiated | BTIG Research | Buy |
| Apr-12-21 | Initiated | Oppenheimer | Outperform |
Gain Therapeutics Inc Stock (GANX) Latest News
What analysts say about Gain Therapeutics Inc. stock outlookFree Best Stocks to Buy Today - Newser
Is Heron Therapeutics Inc. stock a good hedge against inflationDaily Gain Forecast - Newser
Gain Therapeutics Announces $7 Million Public Offering - TipRanks
Form 424B5 Gain Therapeutics, Inc. - StreetInsider
Why Gain Therapeutics Inc. stock attracts strong analyst attentionDaily Stock Radar - beatles.ru
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - The Manila Times
Gain Therapeutics on pricing stock-and-warrants offering - TradingView
Gain Therapeutics Secures $7M Funding to Advance Novel Parkinson's Treatment Pipeline - Stock Titan
US Futures Trade Mixed As June Inflation Ticks Up: ASML, Morgan Stanley, Goldman Sachs, BofA Earnings In Focus - Benzinga
Why Data Storage Shares Are Trading Higher By 35%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics' High-Stakes Gamble: Can GT-02287 Rewrite the Neurodegenerative Treatment Playbook? - AInvest
Gain Therapeutics Plans Public Offering of Common Shares, Warrants - MarketScreener
Gain Therapeutics falls on equity offering plans - TradingView
Gain Therapeutics Announces Proposed Public Offering - The Manila Times
Gain Therapeutics stock falls after announcing public offering By Investing.com - Investing.com Canada
Gain Therapeutics stock falls after announcing public offering - Investing.com
Gain Therapeutics, Inc. Proposes Underwritten Public Offering of Common Stock and Warrants - Quiver Quantitative
Gain Therapeutics Unveils Strategic Public Offering: Funding Next-Gen Parkinson's Treatment Development - Stock Titan
Why Alaunos Therapeutics Inc. stock attracts strong analyst attentionRapid Gain Targets - Newser
How Atossa Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
How Maze Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
What makes Gain Therapeutics Inc. stock price move sharplyReturn Optimized Trade Insights - Newser
What makes Akero Therapeutics Inc. stock price move sharplyFree Access to Community - Newser
Why Sangamo Therapeutics Inc. stock attracts strong analyst attentionDaily Gain Forecast - Newser
What makes Tango Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
What makes Spero Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
How Gain Therapeutics Inc. stock performs during market volatilityMomentum Swing Watchlist - Newser
What makes Lexeo Therapeutics Inc. stock price move sharplyDaily Gain Forecast - Newser
Why Cabot Corporation stock attracts strong analyst attentionFree Step-by-Step Investment Guide - Newser
How Enliven Therapeutics Inc. stock performs during market volatilityDaily Gain Forecast - Newser
Why Design Therapeutics Inc. stock attracts strong analyst attentionFree Stock Investment Growth Plan - beatles.ru
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives $8.20 Consensus Target Price from Brokerages - Defense World
Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight - The Malaysian Reserve
Beam Therapeutics (BEAM) Surges 5.7%: Is This an Indication of Further Gains? - Yahoo Finance
Analysts Offer Insights on Healthcare Companies: RxSight (RXST), Gain Therapeutics (GANX) and Edwards Lifesciences (EW) - The Globe and Mail
Parkinson's Disease Pipeline Appears Robust With 130+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Institutional investors are Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) biggest bettors and were rewarded after last week's US$47m market cap gain - Yahoo Finance
HC Wainwright Reaffirms Buy Rating for Gain Therapeutics (NASDAQ:GANX) - Defense World
Gain Therapeutics stock advances as Phase 1b trial enrollment exceeds expectations - Investing.com India
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation - TradingView
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note - MSN
Gain Therapeutics Doubles Authorized Common Stock Shares - TipRanks
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement - TradingView
SpringWorks Therapeutics (SWTX) Continues Strong Yearly Run, Showing Over 29% YTD Gain - Daily Chhattisgarh News
Aquestive stock gains on FDA review for allergy drug (AQST) - Seeking Alpha
Stellantis (NYSE:STLA) Receives Consensus Rating of “Hold” from Analysts - Defense World
Gain Therapeutics, Inc. (NASDAQ:GANX) Given Consensus Rating of “Buy” by Analysts - Defense World
Pharmaceutical Stocks Worth Watching – June 13th - Defense World
CRISPR Therapeutics Gains 14% in a Month: How to Play the Stock? - Yahoo Finance
Gain Therapeutics to Participate in Upcoming Investor Conferences - Bluefield Daily Telegraph
Gain Therapeutics Opens Access to Management: CEO Featured at Two Major Biotech Investor Conferences - Stock Titan
Gain Therapeutics Inc Stock (GANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):